1265-P: Relationship between Oral Frailty and Sarcopenia in Older Japanese with Type 2 Diabetes

Introduction: Oral frailty (OF) is a condition in which oral functions are impaired. We investigated the prevalence of OF in older Japanese type 2 diabetes (T2D) and the relationship with sarcopenia. Methods: This cross-sectional study was conducted between February and November 2023 and comprised T2D aged ≥65 years who were admitted to our hospital. At admission, we evaluated glycemic control (HbA1c), sarcopenia (skeletal muscle mass index [SMI], grip strength), and OF prevalence. Oral functions were evaluated using the checklist of the Japanese Association for Dental Science; those with three or more of seven items were diagnosed as OF. Results: Thirty-five individuals were examined: age 75.2±5.4 years, 24 male/11 female, SMI 7.0±1.5 kg/m2, grip strength 22.1±7.6 kg, HbA1c 8.5±2.5%. Of them, 17 (48.6%) were diagnosed with sarcopenia and 30 (85.7%) with OF. When the criteria of sarcopenia and OF were delineated by gender, saliva volume (r=0.610, p=0.003) and masticatory function (r=0.566, p=0.007) were found to be positively associated with grip strength in men. In multi-regression analysis (explanatory variables: age, SMI, saliva volume, and masticatory function), saliva volume was showed a significant association (β=0.481, p=0.033) in men. Conclusion: There is a close relationship between OF and sarcopenia in older Japanese T2D, underscoring the importance of medical-dental collaboration in diabetes care. Disclosure Y. Takahashi: None. S. Kubota: None. M. Sakai: None. T. Kato: None. K. Takao: None. M. Mizuno: None. T. Hirota: None. Y. Horikawa: None. D. Yabe: Advisory Panel; Novo Nordisk. Speaker's Bureau; Novo Nordisk. Research Support; Novo Nordisk. Advisory Panel; Boehringer-Ingelheim. Speaker's Bureau; Boehringer-Ingelheim. Research Support; Boehringer-Ingelheim. Advisory Panel; Eli Lilly and Company. Speaker's Bureau; Eli Lilly and Company. Research Support; Eli Lilly and Company. Advisory Panel; Sanofi. Speaker's Bureau; Sanofi, Sumitomo Dainippon Pharma Co., Ltd., Kyowa Kirin Co., Ltd. Research Support; Terumo Corporation, Taiho Pharmaceutical Co. Ltd.